ATYR 1923

Drug Profile

ATYR 1923

Alternative Names: ATYR-1923; iMod.Fc; Stalaris

Latest Information Update: 04 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator aTyr Pharma
  • Class Antifibrotics; Proteins; Recombinant fusion proteins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Interstitial lung diseases
  • Preclinical Pneumonia; Pulmonary fibrosis

Most Recent Events

  • 26 Jun 2018 aTyr Pharma plans a phase II trial for Interstitial lung diseases in 4Q of 2018
  • 26 Jun 2018 Adverse events and pharmacokinetics data from the phase I trial in Interstitial lung disease (In volunteers) released by aTyr Pharma
  • 18 May 2018 Pharmacodynamics and pharmacokinetics data from preclinical studies in Interstitial lung diseases presented at the 114th International Conference of the American Thoracic Society (ATS-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top